Team

Talented laboratory scientists, medicinal chemists, and biotech leaders with successful track records in oncological drug development.

Science and Operations

  • Photo: Greg Crimmins

    Greg Crimmins

    CEO, Founder

    Ph. D.

    Greg has a PhD in molecular biology from University of California, Berkeley, where he helped invent a promising new way to treat cancer with immunotherapy. He has 20 years of experience in biomedical research, including phenotypic screening, cell biology, and immunology. Greg has led Remedy Plan from inception through development of its drug screening platform to the optimization of novel first-in-class cancer therapeutics.

  • Photo: Dennise A. De Jesús-Díaz

    Dennise A. De Jesús-Díaz

    Executive Director of Scientific Operations

    Ph. D.

    Dennise provides project leadership for our scientific operations and is responsible for development and implementation of effective research practices. She has worked in biomedical research for over 10 years, most recently at the National Institutes of Health. She holds a B.S. from the University of Puerto Rico at Cayey and a Ph.D. from Tufts University School of Medicine.

  • Photo: Yushma Bhurruth-Alcor

    Yushma Bhurruth-Alcor

    Lead Scientist - Medicinal Chemistry

    Ph.D.

    Yushma brings extensive pharmaceutical drug discovery experience to the Remedy Plan team. She has worked for 10 years in the pharmaceutical industry for companies such as GlaxoSmithKline, Galderma-NSH, and Johnson & Johnson, where she successfully developed new clinical drug candidates. After graduating from the ESPCI in Paris, Yushma obtained her Ph.D. in Chemistry from Imperial College London.

  • Photo: Caroline Robb

    Caroline Robb

    Research Scientist I

    Ph.D.

    Caroline joins the Remedy Plan team with a strong background in oncology drug discovery. She received her Ph.D. in Cancer Research from the University of Nebraska Medical Center and conducted her postdoctoral research as a fellow at Memorial Sloan Kettering Cancer Center in NYC. Throughout her training, Caroline has focused on characterization of mechanisms of action and target identification studies to identify new cancer therapies.

  • Photo: Adam Lynch

    Adam Lynch

    Research Technician

    M.S.

    Adam graduated from Longwood University with a B.S. in biology and went on to receive his M.S. from Indiana University of Pennsylvania. With his previous experience contributing to research projects in the fields of tumor immunology and pharmacology, Adam joins the team to accelerate Remedy Plan’s drug discovery efforts.

  • Photo: Allison Crimmins

    Allison Crimmins

    Director Of Strategy

    M.S., M.P.P.

    Allison is an environmental scientist with a degree in public policy from the Harvard Kennedy School. She has expertise in leading large scale collaborative research publications and scientific assessments across private, government, and academic institutions, and a knack for communicating complex concepts in accessible language.

Scientific Advisory Board

  • Photo: Frank McCormick

    Frank McCormick

    Advisor

    Ph.D., FRS, DSc

    Frank is a Professor at the University of California San Francisco (UCSF) Comprehensive Cancer Center and founder of Onyx Pharmaceuticals, where he initiated drug discovery efforts that led to the approval of multiple cancer treatments (renal cell, liver, and nasopharyngeal). Frank is a Fellow of the Royal Society (FRS) and member of the National Academies of Science.

  • Photo: Daniel Portnoy

    Daniel Portnoy

    Advisor

    Ph. D.

    Daniel is a Distinguished Chair in Global Public Health and Infectious Diseases and Professor of Biochemistry, Biophysics and Structural Biology at the University of California Berkeley. He is a member of the National Academies of Science, an NIH Merit Award recipient, and serves on the advisory board of Aduro Biotech, a clinical-stage cancer immunotherapy company.

  • Photo: Vahe Bedian

    Vahe Bedian

    Advisor

    Ph.D.

    Vahe is retired from a career in cancer pharmaceutical R&D, biotherapeutics, and immuno-oncology. He is currently serving as a consultant and advisor to biotechs and non-profits.

  • Photo: Ronald Parchem

    Ronald Parchem

    Advisor

    Ph.D.

    Ron is a professor in Baylor's Department of Neuroscience at the Stem Cells and Regenerative Medicine Center, where his research focuses on neural development, stem cells, and cancer biology. He received his Ph.D. from U.C. Berkeley and did his post-doctoral fellowship at U.C. San Francisco.

Business Mentors

  • Photo: Sol Graham

    Sol Graham

    Maryland Venture Mentor Service Mentor

    Sol is founder and CEO of Quality Biological, Inc., a primary manufacturer of supplies for cell culture and molecular biology applications. He has served on the Board of Directors for Montgomery General Hospital, Macklin Business Institute, and the Strathmore Hall Foundation, among others, and has chaired the Economic Advisory Council of Montgomery County.

  • Photo: Chris Efessiou

    Chris Efessiou

    Maryland Venture Mentor Service Mentor

    Ph.D.

    Christos is founder and CEO of Strategic Pharmaceutical Advisors (SRxA), a life sciences strategic consulting, marketing, and communication company. His career spans 25+ years of experience in pharmaceutical marketing, sales, and product management; market research and planning, and clinical practice in respiratory care and extracorporeal circulation.

  • Photo: Vic Schmitt

    Vic Schmitt

    Maryland Venture Mentor Service Mentor

    MBA

    Vic has been a Venture Partner and Advisor to Bay City Capital since 2007. He was formerly President of Venture Management at Baxter Healthcare Corporation where he  was responsible for the creation and management of Baxter Healthcare’s interests in development-stage biotech companies. He has served on the board of directors of more than a dozen development-stage biotech companies.